Equities

P3 Health Partners Inc

PIII:NAQ

P3 Health Partners Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.215
  • Today's Change0.011 / 5.50%
  • Shares traded381.62k
  • 1 Year change-81.14%
  • Beta0.9948
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from more than 250 disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 2,800 affiliated primary care providers across the country. Its local teams of health care professionals manage the care of thousands of patients in 23 counties across five states.

  • Revenue in USD (TTM)1.48bn
  • Net income in USD-102.69m
  • Incorporated2020
  • Employees400.00
  • Location
    P3 Health Partners Inc2045 W Grand Ave Ste B, Pmb # 82152CHICAGO 60612-1577United StatesUSA
  • Phone+1 (312) 822-8897
  • Fax+1 (302) 636-5454
  • Websitehttps://ir.p3hp.org/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regencell Bioscience Holdings Ltd0.00-4.30m73.52m12.00--8.95-----0.3306-0.33060.000.63160.00----0.00-41.44-56.31-42.99-77.51------------0.00------26.73------
VolitionRX Ltd1.29m-29.87m74.69m110.00------58.09-0.3623-0.36230.0155-0.23280.0837--7.4111,689.36-196.61-111.92---196.20-----2,348.71-10,793.31---104.15----153.04---16.68--29.13--
Ovid Therapeutics Inc631.56k-32.50m75.23m25.00--0.9866--119.12-0.4598-0.45980.00891.070.0056----15,789.00-28.55-20.78-31.34-23.27-----5,146.15-56.16----0.00---73.93--3.38---17.14--
Adicet Bio Inc0.00-117.88m75.31m143.00--0.356-----1.70-1.700.002.570.00----0.00-49.20-37.03-53.58-40.28-------748.46----0.00---100.00---104.41--65.27--
Aerovate Therapeutics Inc0.00-84.61m75.34m51.00--0.936-----2.99-2.990.002.790.00----0.00-72.99---81.83--------------0.00-------46.61------
Armata Pharmaceuticals Inc5.47m-41.36m75.98m66.00------13.90-1.24-1.240.1312-1.410.0518--1.0282,833.34-39.21-59.78-116.66-72.70-----756.59-1,113.72----1.90---17.77---87.03--184.10--
P3 Health Partners Inc1.48bn-102.69m76.91m400.00--0.289--0.0521-0.753-0.75311.080.7441.71--12.283,691,575.00-28.94---83.29---2.720.1781-16.95-56.93---12.940.3358--20.6770.5878.61---11.20--
Clearside Biomedical Inc7.70m-31.88m77.36m30.00------10.04-0.4503-0.45030.1094-0.46540.2423--9.23256,766.70-100.27-63.57-122.24-81.7797.01---413.83-231.80--------519.89207.341.40--82.41--
ESSA Pharma Inc0.00-27.67m78.12m50.00--0.606-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Sellas Life Sciences Group Inc0.00-32.28m78.49m16.00--4.94-----0.7113-0.71130.000.24680.00----0.00-186.64-111.48-527.32-184.29-------1,289.42----0.00---100.00--9.59------
CervoMed Inc10.07m-11.95m79.07m8.00--1.73--7.85-1.60-1.601.355.530.3305----1,258,319.00-39.22-53.67-43.28-58.89-----118.68-949.54----0.00------86.07------
Werewolf Therapeutics Inc3.39m-62.12m79.32m45.00--0.8707--23.43-1.50-1.500.08192.040.0214--1.0672,042.55-39.26---42.91-------1,834.55------0.2228--21.60--30.56------
Renovaro Inc0.00-115.69m79.49m25.00--0.8047-----0.9343-0.93430.000.62230.00----0.00-128.97-39.86-158.19-42.11-----------9.650.0259-------103.23---37.12--
PDS Biotechnology Corp0.00-40.56m81.00m25.00--3.68-----1.17-1.170.000.59750.00----0.00-73.98-51.63-98.74-59.00-----------19.130.5286-------5.11------
Allakos Inc0.00-178.75m81.03m131.00--1.11-----2.03-2.030.000.81420.00----0.00-87.64-42.71-97.01-45.11------------0.00------41.96---38.89--
Data as of Nov 21 2024. Currency figures normalised to P3 Health Partners Inc's reporting currency: US Dollar USD

Institutional shareholders

19.54%Per cent of shares held by top holders
HolderShares% Held
Alyeska Investment Group LPas of 30 Sep 202415.70m9.70%
Armistice Capital LLCas of 30 Sep 20246.65m4.11%
Morgan Stanley & Co. LLCas of 30 Sep 20241.91m1.18%
The Vanguard Group, Inc.as of 30 Sep 20241.80m1.12%
Corient Private Wealth LLCas of 30 Sep 20241.73m1.07%
EMFO LLCas of 30 Jun 20241.43m0.88%
Geode Capital Management LLCas of 30 Sep 20241.03m0.64%
Millennium Management LLCas of 30 Sep 2024486.23k0.30%
Renaissance Technologies LLCas of 30 Sep 2024484.50k0.30%
Abundance Wealth Counselors LLCas of 30 Sep 2024400.00k0.25%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.